October 10th, 2009. Dr. Dharminder Chauhan (Dana Farber Cancer Institute, Boston, MA) will present exciting new data on the activity of Progenra’s USP7 inhibitor, P5091 against cell based and in vivo models of multiple myeloma at the 51st ASH Annual Meeting and Exposition. Dr. Chauhan’s oral presentation entitled “Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma” will be presented in the Myeloma – pathophysiology and preclinical studies excluding therapy: targeting intracellular proteolysis and the cell surface session at 3:30pm on Monday December 7th, 2009.

Read More

The drought in New Chemical Entities (NCEs) in the marketplace is the result of many organizations having developed specific molecular-targeted agents that subsequently failed in the clinic. These failures can be attributed to traditional methods for evaluating compound recommendations for clinical trial and the inability to bring new technologies to bear at the pre-clinical stage. At Progenra we believe that greater scrutiny of compounds at the pre-clinical stage will significantly increase clinical success rates.
Read More

Progenra is developing compounds targeting the ubiquitin pathway for in house clinical development. In addition, a number of compounds at different stages of development, which address various therapeutic areas and novel molecular targets, are available for co-development through a partnership.
Read More